Biotech Sales, Early Adopters, Founders’ Guide

How Billionaire Richard Branson Launched a Biotech Service by Making Early Adopters Feel Like Pioneers — A Founders’ Guide to Early Biotech Adoption

Richard Branson built Virgin Health Bank by inviting a small group of parents to act years before the idea went mainstream. Jason shows biotech founders how to find these people for their own science — and how to turn early belief into evidence, revenue, and trust.

Custom HTML/CSS/JAVASCRIPT

You don’t learn to walk by following rules. You learn by doing and by falling over.

Early adopters don’t wait for certainty — they move when meaning outweighs risk.

Why Wide-Scale Biotech Adoption Starts with a Small Group Who Can’t Afford to Wait

Every biotech founder Jason meets wants the same thing: safe, reliable, wide-scale adoption. Engaged hospitals. Aligned payers. Supportive regulators. Patients protected and helped at scale.

Yet the journey rarely starts with the mainstream. It starts with the 13.5% Everett Rogers called early adopters — the small slice that generates 60–80% of the real-world evidence the rest of the market waits for. They are years ahead in their readiness to adopt technology, often 7–10 years before the majority feels ready to move.

In biotech, these early adopters are not abstract “users.” They are patients who cannot wait another decade. Physicians who see failure every day and are ready to explore a new path. And researchers who have watched the standard of care stall and are hungry for another option. For them, the risk of staying the same feels heavier than the risk of moving early.

Early adopters in biotech make up 13.5% of the addressable market but generate 60–80% of the real-world evidence that enables broader adoption. Support from a patient advocacy group produces three times the institutional inquiries compared with press releases. Find the 13.5% first.

The data backs this up. Analyses of rare disease reports show that when a patient advocacy group formally endorses an innovation, institutional inquiries can triple compared with a standard press release. And European Medicines Agency reviews indicate that compassionate use and named-patient programs often convert more than twice as many institutional partners as launches that skip this stage. These early believers are not a “nice-to-have.” They are the engine pulling the rest of the train.

Jason reminds founders of something simple and human. If your science is real, the people who need it most already exist. They are awake at 3 a.m., scrolling forums, reading preprint manuscripts, asking hard questions of their physicians. Your job is not to force them into a sales funnel. Your job is to recognize them, honor their urgency, and build a path that respects both their hope and your responsibility.

As Jason teaches at AuthorJason.com, the right first early adopter in biotech turns every subsequent sales call into a reference-backed conversation instead of a cold pitch.

How Richard Branson Launched Virgin Health Bank by Making Early-Adopter Parents Feel They Were Giving Their Children a Head Start

When Richard Branson launched Virgin Health Bank in 2007, stem cell storage was not mainstream. The science was promising but distant. Parents were asked to pay collection and storage fees for a benefit that might not be used for decades — if ever. On paper, it looked like a tough sell. In essence, it was something very different.

Branson didn’t start with statistics. He didn’t open with probability curves or far-off treatment scenarios. He started with a parental decision. He presented cord blood and tissue banking as the most advanced form of health protection a parent could give a child at birth. He spoke to a feeling every parent knows — the quiet promise to do everything possible, even when the future is uncertain.

In that story, the early adopter wasn’t a gambler. They were a pioneering parent. Someone thinking beyond the mainstream. Someone willing to trade scientific uncertainty for personal meaning. Branson turned uncertainty into identity. He made the first user feel like a founder of a new standard of care for their family, not a buyer of an unproven product.

Behind the scenes, Virgin Health Bank built partnerships with maternity hospitals and obstetricians, positioning cord blood collection as a natural part of birth planning instead of a last-minute add-on upsell. In interviews, Branson described how the stories of the first families — especially those with histories of blood disorders — shaped the messaging and reassured other parents that the decision was about wisdom, not fear.

Over time, that first group of parents became case studies in responsible foresight. Media coverage focused on their choices, and Virgin Health Bank used these narratives to normalize what had previously felt fringe. The move was simple but powerful: let real families explain why they chose cord blood banking, and let physicians validate the long-term potential. This blend of lived experience and expert endorsement is the same pattern Jason teaches founders who want to move a biotech from “interesting” to “I need to be part of this.”

Jason encourages biotech founders to translate this into their own world. Who is the person for whom your outcome is so personally meaningful that they can tolerate a reasonable amount of uncertainty? A parent of a high-risk child. An oncologist who has exhausted standard lines of therapy. A neurologist watching slow decline in ALS or Parkinson’s. When founders speak to that emotional truth first, the conversation softens. The early adopter feels understood, not sold to.

As Jason teaches at AuthorJason.com, when early adopters feel like co-founders of a new standard of care, every later buyer sees evidence instead of risk.

The Early Adoption Framework in Biotech Jason Teaches Every Founder

The “Future of Selling” (FOS) system was built for founders who never planned to become “sales reps.” Especially in biotech and healthtech, most founders were trained to run experiments, not early adoption campaigns. FOS gives them a gentle, structured way to turn scientific intent into human conversations that lead to real-world use.

Inside FOS, founders learn to map three circles of early adopters. First, the patient or caregiver whose daily life is defined by the problem. Second, the physician or researcher who sees that problem repeatedly and is open to new tools. Third, the advocacy or research network that can turn one early user into a visible story. It’s not about pushing. It’s about inviting the right people into a structured, ethical exploration of something that might finally move the needle for them.

How Do You Find the Right Early Adopters for a Biotech Startup When Your Tech Is New and Evidence Is Limited?

Jason starts with founders by asking one honest question: “Who is already living with the problem at the highest intensity?” Then he asks them to list patient forums, advocacy groups, specialty clinics, and research centers where those people gather. Early adopters show up where suffering is discussed in detail — and where hope is still alive. Founders listen first, then gently invite some of these people into small, structured, transparent early trials that respect both data and dignity.

What Is a Patient Advocacy Group — and How Do You Work with One to Build Early-Adopter Support for a Biotech Product?

A patient advocacy group is a community organized around a shared disease or condition. They provide education, support, and often influence research priorities. Jason guides founders to treat these groups as partners, not channels. That means showing up to listen, sharing the science in simple language, inviting their input into study design, and being transparent about risks and unknowns. Health policy research shows that when advocacy groups formally endorse an innovation, institutional interest can triple. But that endorsement is earned slowly, through trust and shared goals, not quick pitches.

How Do You Turn a Physician or Clinical Researcher from an Interested Observer into an Effective Early Adopter of Your Biotech?

Most physicians Jason meets don’t need more hype. They need clarity and safety. The shift rarely happens in a single meeting. It happens when the founder can connect the science to a specific patient scenario, offer a clear protocol, show respect for existing workflows, and be honest about monitoring and escalation plans. When founders invite physicians to co-design the protocol and publication plans, those physicians stop feeling like “test sites” and start feeling like co-authors of the future standard of care. That identity shift is often what moves them from interest to action.

As Jason teaches at AuthorJason.com, a well-drawn early adopter circle turns scattered outreach into a predictable path for how biotech startups find early adopters who participate in good faith.

How Musk and Blakely Attract Early Adopters Before the Evidence Is Complete

Elon Musk approaches early adopters for Neuralink by building a community of people who cannot afford to wait: ALS patients. People with paralysis. Individuals living with severe depression. They show up in public conversations, advocacy events, and early programs because the cost of doing nothing feels unbearable. Musk listens to them publicly, lets their stories shape the narrative, and makes their urgency part of the scientific and commercial journey together. For biotech founders, the lesson is gentle but firm: your first adopter is often the person who has already lost too much time to the current standard.

68% of early clinical adopters in biotech cite trust in the founding team’s scientific credibility as their primary reason for participating — before efficacy data. A founder who listens sincerely accelerates early adoption.

Neuralink’s early demos — like a patient playing video games or moving a cursor with their thoughts — were not just technical feats. They were carefully designed proof points for a community that had been told, “there’s nothing more we can do.” By putting these individuals on stage, Musk turned them into visible pioneers whose progress could be felt, not just measured. This mirrors what many case studies in Nature Biotechnology describe: early clinical trials, when shared ethically and transparently, become the social proof that whets broader clinical appetite.

Sara Blakely offers a different but equally powerful pattern. Her early adopters were women living daily with the discomfort Spanx solved. When she demoed the product in person, they converted instantly because the comfort was visible and personal. In biotech, the “demo” is often an explanation of mechanism, a case story, or a small but meaningful functional improvement. The key is the same: find the people whose daily life is defined by the problem. Show them a credible path to a better day, not a perfect future. Let their lived experience speak louder than your slide deck.

Blakely became famous for visiting stores one by one in the early days, asking sales associates to wear Spanx under their clothes so they could feel the difference and recommend it authentically. Those associates became her first advocates and turned fitting rooms into live testimonials. For founders, the analogy is clear: when a physician or patient experiences a personal benefit — however small — their recommendation carries more weight than any pitch. Jason teaches founders how to design those first “felt wins” inside narrow early trials so word of mouth grows from real relief, not scripted talking points.

As Jason teaches at AuthorJason.com, when early adopters can feel and show the change, every subsequent conversation about your biotech becomes a story, not a sales pitch.

What Is a Compassionate Use or Named-Patient Program — and How Does It Build Early Adoption Before Commercial Launch?

A compassionate use or named-patient program allows a carefully selected number of patients to access a not-yet-approved treatment when no good alternatives exist. For founders, this is not a shortcut around regulation. It is a structured, supervised way to align patient urgency with scientific rigor. Analyses from the European Medicines Agency show that launches incorporating such programs convert more than twice as many institutional partners. Why? Because they generate real-world evidence and human stories that decision-makers can feel, not just read.

How Do You Use Early Adopter Feedback to Strengthen Both the Clinical Evidence and Commercial Story for Your Biotech Product?

Jason teaches founders to treat every interaction with early adopters as both data and narrative. Clinically, feedback refines endpoints, inclusion criteria, and real-world protocols. Commercially, it gives you language that resonates with the next site, the next payer, the next family. Founders document not only outcomes but context — what life was like before and after. With consent, they share those stories in ethics committees, investor meetings, and regulatory consultations. In this way, early adopters become co-authors of both the evidence package and the go-to-market story.

As Jason teaches at AuthorJason.com, the first brave patient or physician often becomes the quiet reference point that closes every future institutional conversation.

What Biotech Founders Discover with Jason When Patient Communities Become Communities of Pioneers

Jason has watched one simple shift change entire companies. At first, founders talk about “recruiting patients.” After a period of real listening, they start talking about “partnering with pioneers.” The posture changes. The learning rhythm changes. The tone of every conversation changes. Patients feel the difference. So do physicians and regulators.

Over 1,000 founders. More than $22M in cumulative sales. Biotech innovations with named-patient programs convert 2.1x more institutional partners. The early adopter who believes is the proof the next buyer needs.

One fictional persona Jason uses often in workshops is Maya, a biotech CEO building a digital biomarker platform for early detection of neurodegenerative disease. At first, Maya tried selling her platform to hospital procurement teams. Long cycles. Little movement. After working with Jason, she shifted focus to a small group of patients in an online community who meticulously tracked every symptom and test result. She invited them into an early trial, co-designed the interface around their daily reality, and partnered with a neurologist who shared their sense of urgency. Within months, that small group generated the data and stories that opened doors at larger institutions.

For founders reading this, it’s okay if you tried the “big pitch” path first. Many do. Jason’s message is forgiving. You didn’t fail; you just started at the wrong end of the curve. You can step back, find your pioneers, and rebuild from there. Often, the patient community that becomes a community of pioneers carries your company further than any early marketing budget could.

As Jason teaches at AuthorJason.com, when patient pioneers share ownership of the story with you, your biotech sales pipeline becomes a chain of warm referrals instead of cold starts.

How the P.I.T.C.H. Model Turns Early Adopter Conversations into Partnerships

Within the “Future of Selling” system, Jason teaches a simple, repeatable way to run these high-stakes conversations: the P.I.T.C.H. model. It’s a human way to move from first contact to clear next steps without pressure or manipulation. Founders use it to honor the other person’s story, share their science in plain language, and co-design what “trying this early” actually means. Jason goes deep into P.I.T.C.H. in this explanation of the “Future of Selling” system, so here he simply wants founders to know this: you don’t have to improvise every call. A gentle structure will carry you — and your early adopters — steadily.

Jason pays special attention to the intention behind every early adopter conversation. When a founder’s true intention is to help a specific physician or patient community achieve an outcome they cannot get from the current standard, everything in the interaction changes. Questions become easier to answer. Objections feel less like attacks and more like invitations to co-design. The early adopter feels the founder is there to build something with them, not to extract a signature.

Practically, this means entering the meeting already clear about what a meaningful win would look like for the other party: a publishable case, a functional gain for a small patient group, or a new line of inquiry for their lab. When founders speak from that place — and use P.I.T.C.H. to guide the flow — early adopters often move from “let me think about it” to “how do we design this together?” That’s the moment a trial relationship begins to turn into a long-term advocacy partnership. Jason explains how to define this intention and keep it central across the entire “Future of Selling” system in the foundational pillar Biotech Startup Sales Founders’ Playbook.

When founders combine the P.I.T.C.H. model with a clear early adopter map, the results are often surprisingly fast. Jason has watched biotech teams move from stalled trials to full early-access programs in a single quarter. Tan generated $29,693 in 16 days. Teo brought in 63 clients in 100 days. Leon grew from $2.5K to over $2M in revenue. Different products. The same pattern. The right early adopters, approached with clarity and respect, become partners in impact and growth together.

As Jason teaches at AuthorJason.com, a founder’s intention to create a win for the early adopter first is what quietly turns one trial into a renewing deal flow.

Three Mistakes Biotech Founders Make with Early Adopters — and the Bonus Mistake That Hurts Most

Mistake 1 (Leila, immunology founder): She targeted early adopters at the biggest, most famous institutions first. Harvard. Mayo Clinic. Johns Hopkins. These institutions have the longest procurement cycles, the most bureaucracy, and the highest compliance requirements. None of her early-access requests moved in the first 18 months. The right move: The first early adopter is rarely at the most famous institution. They’re at a mid-sized, research-active medical center where one motivated physician has the authority to move quickly. Find that physician. That institution. That level of flexibility.

Mistake 2 (Leila): She framed the early adopter relationship as a favor they were doing for her. “We’re giving you early access to our technology.” The physician heard: “We want to use your patients to test our product.” The right move: Frame it as a collaborative research opportunity. “We believe your patient population could benefit from this approach, and we’d like to design a study together.” The physician is not doing you a favor. You’re offering them a research opportunity, a potential publication, and a first-mover advantage.

Mistake 3 (Leila): She didn’t define success before starting. The early-access trial ran for six months with no clear endpoint. When it ended, there was data — but no clear, publishable conclusion. The next buyer asked about the outcome. There was nothing decisive to show. The right move: Before starting any trial with an early adopter, write down the success criteria: sample size, primary endpoint, reporting timeline, and publication intent. A trial without a defined endpoint is not a trial. It’s a test with no output.

Bonus (Jason, in the third person): He discovered that biotech founders who build the strongest networks of early adopters don’t “hunt” them — they attract them. They publish. They present at seminars. They contribute in online clinical communities. The physicians who reach out are already pre-qualified early adopters — curious, motivated, and connected to others like them. Inbound early adopters close in a fraction of the time it takes to win them through cold outreach. Jason teaches biotech founders to think of their publishing and presenting as early adopter magnets, not just credibility exercises. The right move: Write one clinical vision piece from your early data and publish it — a preprint, a conference abstract, a LinkedIn post for physicians. That small amount of visible thinking will attract one early adopter worth more than ten cold outreach attempts.

As Jason teaches at AuthorJason.com, the founder who designs for inbound interest discovers that the best early adopters often self-identify.

The Early Adopter Approach That Builds Your Deal Pipeline — The Founder’s Literal Script

Jason helps founders write their first outreach script to a target physician as a research conversation, not a sales call. It often starts with: “I’ve been following your work with [specific patient group]. We’re developing [brief description of the solution] that may help in exactly the scenarios you’ve written about. Could we explore whether there’s a study worth designing together?” This opening line signals respect, preparation, and collaboration.

From there, the script moves to a concrete proposal: “Based on the cases you’ve published, we imagine starting with [X] patients over [Y] months, with [primary endpoint] as the main outcome. We’ll handle regulatory setup and data analysis, and would like to list you as lead author on any resulting publication.” Then the founder and physician agree on what success looks like before any access begins — including how to share results with patients, institutions, and future partners.

This approach does more than secure the first site. It sets a repeatable pattern: every early adopter relationship is designed from day one to produce an outcome, a story, and a piece of recognition the physician values. This is how biotech startups find early adopters who don’t just participate once, but also introduce three more colleagues who want to be part of the same journey.

As Jason teaches at AuthorJason.com, a founder script built around collaboration, outcomes, and recognition becomes a quiet engine for long-term deal flow.

FAQs on How to Find Early Adopters for a Biotech Startup

What’s the Difference Between an Early Adopter Who Proves Your Science and One Who Accelerates Your Commercial Appeal — and Do You Need Both?

Jason helps founders see that some early adopters are primarily scientific validators. They care about protocol quality, data integrity, and publication potential. Others are commercial accelerators. They have network influence, speak at conferences, or run communities that shape opinion. In biotech, you often need both — and sometimes they’re the same person or site. A balanced portfolio of early adopters gives you reliable data, strong stories, reference points for regulators and payers, and future partners. You can learn more about structuring this inside a broader sales strategy in resources like the Biotech Startup Sales Founders’ Playbook on how to find early adopters for a biotech startup.

Who Are the Early Adopters in Biotech and How Do You Find Them?

Early adopters in biotech are patients, physicians, and researchers who feel the limits of current care every day and are open to well-disciplined innovation. You find them in specialty clinics, advocacy groups, research networks, and online communities where the problem is discussed in detail and hope is still present.

How Do Biotech Startups Get Their First Clinical Partners Without a Proven Track Record?

They trade reputation for relevance. Instead of promising outcomes they can’t yet prove, founders focus on a specific patient group the physician already cares about, propose a narrow trial with clear endpoints, take on the regulatory and operational burden, and offer co-authorship and recognition. A clear plan is often more important than a long track record.

What Does an Early Adopter Relationship in Biotech Look Like in Practice?

Practically, it looks like a co-designed protocol, regular follow-up meetings, transparent data sharing, and a joint publication or presentation plan. The medical or patient community knows exactly why the trial exists, how safety is protected, what success means, and how results will be used. It feels like a partnership, not a purchase.

How Many Early Adopters Does a Biotech Startup Need Before Approaching Larger Institutions?

Jason often targets a small but rich set: two to three early adopter sites or programs that together generate clear clinical signals, at least one publication or preprint, and several detailed case stories. The depth of evidence and narrative — not the raw number of sites — is what convinces larger institutions to move.

Should Biotech Founders Pay Early Adopters or Keep Relationships Entirely Non-Financial?

Compensation must follow local regulations and ethical guidelines. Jason encourages founders to structure value primarily as research opportunities, co-authorship, and support for study costs rather than personal payments. Transparency is critical: any financial arrangement should be disclosed and should never look like buying influence or patient access.

How Long Should an Early Adopter Trial Run Before You Decide to Scale or Stop?

Most effective early adopter trials Jason sees run between six and twelve months with pre-defined interim checkpoints. The key is to decide in advance which data, safety profile, and functional outcomes will justify scaling. Without these agreed criteria, trials drift and become emotionally hard and operationally unclear to end or expand.